Trial Profile

A phase 3 clinical trial of VY-AADC for Parkinson's disease

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 15 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ezaladcigene resoparvovec (Primary)
Indications Parkinson's disease
Focus Registrational; Therapeutic Use
Acronyms RESTORE-2
Sponsors Voyager Therapeutics

Most Recent Events

11 Sep 2020 According to a Neurocrine Biosciences media release, preparations are ongoing for this global registrational trial that will include clinical sites within and outside the U.S.
10 Aug 2020 event According to a Neurocrine Biosciences media release , it plan to initiate the RESTORE-2 Phase 3 global registrational clinical study of VY-AADC (NBIb-1817) in Parkinsons disease during the first half of 2021.
12 Jan 2020 According to a Neurocrine Biosciences media release, the company expects to initiate this trial in 2H 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com